Oncology Archive

A building with a stone facade displays a sign that reads
A Multicenter Phase Ib/II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
A building with a stone facade displays a sign that reads
An Early Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEEL-224 in Patients With Advanced Solid Tumors
A building with a stone facade displays a sign that reads
Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
A building with a stone facade displays a sign that reads
Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Patients With Advanced Solid Tumors
A building with a stone facade displays a sign that reads
A Phase 1, First-in-Human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5525 Alone and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
A building with a stone facade displays a sign that reads
A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator’s Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)
A building with a stone facade displays a sign that reads
Pancreatic Cancer Early Detection Consortium
A building with a stone facade displays a sign that reads
A Phase 1/1b, Multicenter, Open-label, Dose-escalation and A Phase 1/1b, Multicenter, Open-label, Dose-escalation and Pharmacokinetics of ODC-IL2 Administered via Intravenous Infusion in Adult Patients with Advanced or Metastatic Solid Tumors
A building with a stone facade displays a sign that reads
Expanded Access Program (EAP) for Supply of Nirogacestat with SpringWorks Therapeutics, Inc.
A building with a stone facade displays a sign that reads
A Phase 1, Open-label Study to Evaluate Safety, Tolerability, and Pharmacokinetics of an Anti-LILRB2 / PD-L1 Bispecific Antibody SPX- 303 in Patients With Solid Tumors